Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

One of the pro­grams that head­lined Ab­b­Vie’s $63 bil­lion ac­qui­si­tion of Al­ler­gan is be­ing re­turned to its de­vel­op­ers af­ter an FDA re­jec­tion last year.

Ab­b­Vie has ter­mi­nat­ed the li­cense and col­lab­o­ra­tion agree­ment it had with Switzer­land’s Mol­e­c­u­lar Part­ners for abic­i­par, the com­pa­nies an­nounced Mon­day, an ex­per­i­men­tal drug aimed to treat neo­vas­cu­lar age-re­lat­ed mac­u­lar de­gen­er­a­tion and di­a­bet­ic mac­u­lar ede­ma. Abic­i­par was re­ject­ed by the FDA in June 2020 due to what Ab­b­Vie said was an un­fa­vor­able ben­e­fit-risk ra­tio, ac­cord­ing to its de­scrip­tion of the CRL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER